Bellevue Group’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.03M | Sell |
17,038
-50,044
| -75% | -$2.92M | 0.02% | 91 |
|
|
2025
Q4 | $3.62M | Buy |
67,082
+19,469
| +41% | +$937K | 0.07% | 81 |
|
|
2025
Q3 | $2.15M | Buy |
47,613
+10,436
| +28% | +$487K | 0.04% | 95 |
|
|
2025
Q2 | $1.72M | Buy |
37,177
+11,611
| +45% | +$570K | 0.04% | 97 |
|
|
2025
Q1 | $1.56M | Sell |
25,566
-12,547
| -33% | -$731K | 0.03% | 102 |
|
|
2024
Q4 | $2.16M | Buy |
38,113
+1,288
| +3% | +$72K | 0.04% | 107 |
|
|
2024
Q3 | $1.91M | Buy |
+36,825
| New | +$1.73M | 0.03% | 106 |
|
|
2024
Q2 | – | Sell |
-23,436
| Closed | -$1.27M | – | 169 |
|
|
2024
Q1 | $1.27M | Buy |
+23,436
| New | +$1.19M | 0.02% | 114 |
|
|
2023
Q2 | – | Sell |
-1,496
| Closed | -$104K | – | 157 |
|
|
2023
Q1 | $104K | Sell |
1,496
-48,759
| -97% | -$3.44M | ﹤0.01% | 150 |
|
|
2022
Q4 | $3.62M | Buy |
50,255
+43,193
| +612% | +$3.26M | 0.05% | 117 |
|
|
2022
Q3 | $502K | Sell |
7,062
-17,845
| -72% | -$1.29M | 0.01% | 149 |
|
|
2022
Q2 | $1.92M | Sell |
24,907
-603,221
| -96% | -$45.9M | 0.03% | 129 |
|
|
2022
Q1 | $45.9M | Sell |
628,128
-431,219
| -41% | -$29M | 0.53% | 60 |
|
|
2021
Q4 | $66M | Sell |
1,059,347
-243,587
| -19% | -$14.3M | 0.68% | 51 |
|
|
2021
Q3 | $77.1M | Sell |
1,302,934
-160,498
| -11% | -$10.6M | 0.78% | 43 |
|
|
2021
Q2 | $97.8M | Sell |
1,463,432
-621,720
| -30% | -$40.5M | 0.95% | 32 |
|
|
2021
Q1 | $132M | Buy |
2,085,152
+280,680
| +16% | +$17.5M | 1.39% | 20 |
|
|
2020
Q4 | $112M | Buy |
1,804,472
+158,560
| +10% | +$9.75M | 1.28% | 24 |
|
|
2020
Q3 | $99.2M | Buy |
1,645,912
+33,800
| +2% | +$2.03M | 1.37% | 18 |
|
|
2020
Q2 | $94.8M | Buy |
1,612,112
+406,640
| +34% | +$24.3M | 1.34% | 18 |
|
|
2020
Q1 | $67.2M | Sell |
1,205,472
-883,770
| -42% | -$54M | 1.3% | 19 |
|
|
2019
Q4 | $134M | Buy |
2,089,242
+1,152,233
| +123% | +$66M | 2.13% | 12 |
|
|
2019
Q3 | $47.5M | Buy |
937,009
+81,400
| +10% | +$3.83M | 0.88% | 33 |
|
|
2019
Q2 | $38.8M | Buy |
855,609
+159,785
| +23% | +$7.44M | 0.66% | 39 |
|
|
2019
Q1 | $33.2M | Buy |
695,824
+209,000
| +43% | +$10.4M | 1.83% | 12 |
|
|
2018
Q4 | $25.3M | Buy |
486,824
+145,095
| +42% | +$7.8M | 1.66% | 16 |
|
|
2018
Q3 | $21.2M | Buy |
341,729
+80,880
| +31% | +$4.8M | 1.35% | 21 |
|
|
2018
Q2 | $14.4M | Buy |
260,849
+220,849
| +552% | +$11.9M | 1.23% | 27 |
|
|
2018
Q1 | $2.53M | Buy |
+40,000
| New | +$2.57M | 0.25% | 71 |
|
|
2017
Q2 | – | Sell |
-23,000
| Closed | -$1.25M | – | 133 |
|
|
2017
Q1 | $1.25M | Hold |
23,000
| – | – | 0.17% | 92 |
|
|
2016
Q4 | $1.34M | Hold |
23,000
| – | – | 0.28% | 78 |
|
|
2016
Q3 | $1.24M | Hold |
23,000
| – | – | 0.22% | 89 |
|
|
2016
Q2 | $1.69M | Sell |
23,000
-37,000
| -62% | -$2.61M | 0.32% | 78 |
|
|
2016
Q1 | $3.83M | Buy |
+60,000
| New | +$3.78M | 0.7% | 49 |
|
Other funds holding BMY
VCM
VPM
Bellevue Group's BMY Position: Q1 2026 in Review
Bellevue Group reduced its Bristol-Myers Squibb (BMY) stake by 75% in Q1 2026, selling an estimated $2.92M and leaving 17,038 shares worth $1.03M. The position accounts for 0.02% of the portfolio, ranked #91.
Bellevue Group first reported a position in BMY in Q1 2016 and has held it in 34 quarters since. The position peaked at $134M in Q4 2019. 2,517 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Bellevue Group held 17,038 shares of Bristol-Myers Squibb worth $1.03M as of Q1 2026.
- Bellevue Group sold 50,044 Bristol-Myers Squibb shares in Q1 2026, an estimated $2.92M.
- Bristol-Myers Squibb made up 0.02% of Bellevue Group's portfolio in Q1 2026, its #91 holding.
- Bellevue Group first reported a position in Bristol-Myers Squibb in Q1 2016 and has held it in 34 quarters since.
- Bellevue Group's Bristol-Myers Squibb position peaked at $134M in Q4 2019.
- 2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Bellevue Group's 13F filing for Q1 2026, filed 15 May 2026.